IRIS
LIAKOULI, Vasiliki
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.130
EU - Europa 2.021
AS - Asia 829
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 3
AF - Africa 2
Totale 6.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.121
IE - Irlanda 691
CN - Cina 466
SE - Svezia 353
TR - Turchia 309
IT - Italia 243
DE - Germania 199
UA - Ucraina 193
GB - Regno Unito 147
FR - Francia 79
FI - Finlandia 70
BE - Belgio 30
IN - India 24
VN - Vietnam 20
CA - Canada 8
AU - Australia 6
EU - Europa 6
NZ - Nuova Zelanda 4
NL - Olanda 3
BR - Brasile 2
CH - Svizzera 2
IR - Iran 2
RU - Federazione Russa 2
BG - Bulgaria 1
CI - Costa d'Avorio 1
CO - Colombia 1
DK - Danimarca 1
ES - Italia 1
GE - Georgia 1
GR - Grecia 1
HK - Hong Kong 1
HU - Ungheria 1
ID - Indonesia 1
JP - Giappone 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MX - Messico 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
SG - Singapore 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 6.001
Salva come PNG Salva come JPEG
Città #
Jacksonville 775
Chandler 723
Dublin 691
Izmir 201
Ann Arbor 135
Nanjing 121
Boardman 120
New York 109
Lawrence 101
Princeton 101
Wilmington 100
San Mateo 93
L'aquila 72
Beijing 71
Ashburn 63
Woodbridge 51
Dearborn 49
Milan 44
Nanchang 43
Brussels 30
Shenyang 30
Mountain View 27
Seattle 26
Verona 26
Kunming 24
Hebei 22
Jiaxing 22
Dong Ket 20
Changsha 16
Des Moines 16
Los Angeles 16
Rome 15
Tianjin 15
Jinan 13
Hefei 12
Zhengzhou 11
L’Aquila 10
Ningbo 9
Pune 9
Grafing 8
Helsinki 8
Hangzhou 7
Norwalk 7
Philadelphia 7
Shanghai 7
Bremen 6
Salerno 6
Guangzhou 5
Lanzhou 5
Changchun 4
Edinburgh 4
Fremont 4
Houston 4
La Spezia 4
Phoenix 4
Redwood City 4
Taizhou 4
Frankfurt am Main 3
Fuzhou 3
Jinhua 3
Melbourne 3
Naples 3
Redmond 3
Washington 3
Auckland 2
Baotou 2
Bari 2
Cedar Knolls 2
Chengdu 2
Genzano di Roma 2
London 2
Montreal 2
Mumbai 2
New Delhi 2
Orange 2
Paris 2
Pescara 2
Rimini 2
Sant'Ambrogio di Valpolicella 2
Stockholm 2
Taranto 2
Amadora 1
Aquila 1
Ardebil 1
Athens 1
Auburn Hills 1
Bandung 1
Basel 1
Belluno 1
Bournemouth 1
Brisbane 1
Budapest 1
Cava Dei Tirreni 1
Central 1
Centurion 1
Charlotte 1
Chicago 1
Chisinau 1
Chongqing 1
Città di Castello 1
Totale 4.204
Salva come PNG Salva come JPEG
Nome #
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 109
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 97
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 95
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 93
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 92
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 91
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 87
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 87
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 87
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 86
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 85
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 83
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 83
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 80
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 79
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 78
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 77
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. 77
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 76
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 75
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 74
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 74
Cardiovascular disease in primary sjögren’s syndrome 72
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 71
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 70
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 70
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 69
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 69
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 68
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 67
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 67
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 67
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 67
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 67
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 65
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 65
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 65
Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications 64
Interstitial lung disease in systemic sclerosis: current and future treatment. 64
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 63
SDF-1 expression in the skin of SSc patients. 62
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 62
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. 62
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 60
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 59
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 59
Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC) 59
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 59
Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? 59
Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor 59
Cellular players in angiogenesis during the course of systemic sclerosis. 58
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 58
Methotrexate: an old new drug in autoimmune disease. 57
Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. 57
Mesenchymal stem cells transplantation in Systemic Sclerosis: comment on the article by ATJ Maria et al 57
Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28-. T cells in RA patients and correlation with atherosclerotic damage 57
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 56
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 56
Tocilizumab for the treatment of adult-onset Still's disease: Results from a case series 56
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 55
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 55
IMPAIREMENT OF ENDOTHELIAL DIFFERENTIATION FROM MESENCHYMAL STEM CELLS (MSC) IN SYSTEMIC SCLEROSIS (SSC): A NEW TOOL IN PATHOGENETIC MECHANISM 54
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 54
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 53
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome 52
Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC). 52
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 52
ASSOCIATION OF FAS-G670A GENE POLYMORPHISM WITH SYSTEMIC SCLEROSIS 51
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). 51
THE IL-33/ST2 PATHWAY IN SYSTEMIC SCLEROSIS 50
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosis 49
Angiogenic cytokines and growth factors in systemic sclerosis. 49
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 49
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 49
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 49
Pathogenesis of the endothelial damage and related factors. 48
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 48
 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 47
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 47
Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis: pathogenetic implication. 46
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 46
The Vessels Contribute to Fibrosis in Systemic Sclerosis 46
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 46
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial 46
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 46
VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION. 44
null 43
Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives 42
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 42
Endothelial Progenitor Cells (EPC) characterization in systemic sclerosis (SSc) patients 41
THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers 40
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 40
Modificazioni della nitrossido-sintasi neuronale (nNOS) nella cute dei pazienti con sclerosi sistemica (SSc). 39
DIFFERENTIAL EXPRESSION OF SDF-1 AND ITS RECEPTOR CXCR4 IN THE SKIN AND ENDOTHELIAL CELLS OF SYSTEMIC SCLEROSIS PATIENTS: PATHOGENETIC IMPLICATION 38
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis 38
Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 36
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 34
FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis 32
THE OCCURRENCE OF SUBCLINICAL AND CLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS, RESULTS FROM THE 3-YEAR, MULTICENTER, PROSPECTIVE, OBSERVATIONAL, GIRRCS STUDY 31
SCLERODERMA FIBROBLASTS SUPPRESS ANGIOGENESIS VIA TGF-beta/CAVEOLIN-DEPENDENT SECRETION OF PIGMENTED EPITHELIUM DERIVED FACTOR: TGF-beta RECEPTOR INHIBITORS AS A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF SCLERODERMA 29
Totale 6.046
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019254 0 0 0 0 0 0 0 0 0 0 5 249
2019/2020942 154 14 109 15 14 149 150 18 111 45 11 152
2020/2021927 22 106 16 123 110 39 123 7 105 45 171 60
2021/2022637 42 36 162 53 13 10 9 27 44 35 47 159
2022/20232.035 153 127 32 238 160 215 4 118 882 15 63 28
2023/2024452 71 35 28 51 50 158 10 25 1 22 1 0
Totale 6.154